{"id":21533,"date":"2020-06-16T07:00:00","date_gmt":"2020-06-16T07:00:00","guid":{"rendered":"http:\/\/radiofree.asia\/?guid=39a39964537dc4ebc3b1bc4aa1436144"},"modified":"2020-06-16T07:00:00","modified_gmt":"2020-06-16T07:00:00","slug":"vaccine-development-needs-new-incentives-with-tahir-amin","status":"publish","type":"post","link":"https:\/\/radiofree.asia\/2020\/06\/16\/vaccine-development-needs-new-incentives-with-tahir-amin\/","title":{"rendered":"Vaccine development needs new incentives (with Tahir Amin)"},"content":{"rendered":"\n
COVID-19 has exposed the limits of the pharmaceutical market model. This week, patent law expert Tahir Amin joins the show to explain why vaccine development needs new incentives.<\/p>
<\/p>
Tahir Amin is an attorney dedicated to reshaping patent law to better serve the public. He is the Co-Founder and Co-ED of the Initiative for Medicines, Access, and Knowledge (I-MAK), a global nonprofit organization of attorneys, scientists, and health experts working on systemic changes to intellectual property and the political economy of pharmaceutical innovation.\u00a0<\/p>
<\/p>
Twitter: @realtahiramin<\/a><\/p> Further reading:\u00a0<\/p> Covid-19 has exposed the limits of the pharmaceutical market model: https:\/\/www.statnews.com\/2020\/05\/19\/covid-19-exposed-limits-drug-development-model\/<\/a><\/p> No vaccine in sight: https:\/\/newrepublic.com\/article\/157594\/no-coronavirus-vaccine-big-pharma-drug-patent-system<\/a><\/p> Democrats punt on drug-pricing overhaul in virus relief measure: https:\/\/news.bloomberglaw.com\/health-law-and-business\/democrats-punt-on-drug-pricing-overhaul-in-virus-relief-measure<\/a><\/p> Website: http:\/\/pitchforkeconomics.com\/<\/a><\/p> Twitter: @PitchforkEcon<\/a><\/p> Instagram: @pitchforkeconomics<\/a><\/p> Nick\u2019s twitter: @NickHanauer<\/a><\/p>\n \n
<\/p>
<\/p>
<\/p>
<\/p>